Ermium Therapeutics bags €6.3m in Series A round

Domain Therapeutics, Kurma Partners, Idinvest, and the SATT Erganeo contributed to the financing.

Ermium Therapeutics has licenced exclusively global commercialisation rights from CNRS and University Paris Descartes (France) through its patent office Erganeo on CXCR4-agonists to treat indications caused by Toll-like receptor 7 (TLR7)–mediated inflammation. The company has been built on recent findings of Jean-Philippe Herbeuval that demonstrated preclinical efficacy of amines targeting CXCR4 in a lupus model and in an influenza model. Naturally occuring and synthetic amines such as the company's small molecule candidate IT1t block interferon-I secretion from plasmacytoid dendritic cells and thus virally and bacterially triggered inflammation.

Erganeo provided initial funding to generate the first chemical series, opening the door to the discovery of a new class of drugs to be developed by Ermium. The company wants to use the funds for lead optimization and the early development of orally available drug candidates for a wide range of auto-immune diseases.